Our clinical trials

Cantargia’s clinical program

Nadunolimab (CAN04)

The IL1RAP-binding antibody CAN04 is Cantargia’s principal candidate and is investigated in multiple clinical trials in combination with chemotherapy or immunotherapy, summarized in the table below. The clinical program for CAN04 initially focused on non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) but has more recently been broadened to include additional cancer forms.


Overview of Cantargia’s ongoing clinical studies for CAN04.


In the CAN10 project, a new antibody against IL1RAP, customized for treatment of autoimmune and inflammatory diseases, is being developed. The initial focus will be on two severe diseases: myocarditis and systemic sclerosis. CAN10 is currently in late-stage preclinical phase and the goal is to start the first clinical trial in early 2023.